Literature DB >> 18375889

Optimal schedule of paclitaxel: weekly is better.

Ana M Gonzalez-Angulo, Gabriel N Hortobagyi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18375889     DOI： 10.1200/JCO.2007.15.7651

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Targeted therapies: peaking beneath the surface of recent bevacizumab trials.

Authors:  Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Lee M Ellis
Journal:  Nat Rev Clin Oncol       Date:  2011-04-19       Impact factor: 66.675

2.  Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.

Authors:  Markus Joerger; Stefanie Kraff; Alwin D R Huitema; Gary Feiss; Berta Moritz; Jan H M Schellens; Jos H Beijnen; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

3.  Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.

Authors:  Seung Jin Lee; Hye Young Kang; Seog Young Kim; Jin Hwa Chung; Seung Jun Oh; Jin-Sook Ryu; Sung-Bae Kim; Jong Soon Kang; Song-Kyu Park; Hwan Mook Kim; Myung-Hwa Kim; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 4.  PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery.

Authors:  Hyunah Cho; Jieming Gao; Glen S Kwon
Journal:  J Control Release       Date:  2015-12-15       Impact factor: 9.776

5.  Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.

Authors:  Rong Liu; Aaron H Colby; Denis Gilmore; Morgan Schulz; Jialiu Zeng; Robert F Padera; Orian Shirihai; Mark W Grinstaff; Yolonda L Colson
Journal:  Biomaterials       Date:  2016-06-23       Impact factor: 12.479

Review 6.  The role of taxanes in triple-negative breast cancer: literature review.

Authors:  Giorgio Mustacchi; Michelino De Laurentiis
Journal:  Drug Des Devel Ther       Date:  2015-08-05       Impact factor: 4.162

7.  Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.

Authors:  D Lu; A Joshi; H Li; N Zhang; M M Ren; Y Gao; R Wada; J Y Jin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-05-21

8.  Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.

Authors:  Georgia Kourlaba; Vasiliki Rapti; Athanasios Alexopoulos; John Relakis; Georgios Koumakis; Magdalini Chatzikou; Nikos Maniadakis; Vassilis Georgoulias
Journal:  BMC Health Serv Res       Date:  2015-08-05       Impact factor: 2.655
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.